Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028870 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee
A Phase 2 study, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 291
- Enrollment target
NCT03028870 is a Phase 2 study that has completed, run by Purdue Pharma. The registered enrollment target is 291 participants.
The verdict
NCT03028870, a Phase 2 study, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 291 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the analgesic efficacy of V120083 twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.
Interventions
- DRUG Placebo
- DRUG Naproxen
- DRUG V120083
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2017-03-14 |
| Est. Completion | 2017-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03028870
The ClinicalTrials.gov registry entry for NCT03028870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03028870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03028870 about?
NCT03028870 is a clinical study titled "A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee". The purpose of this study is to evaluate the analgesic efficacy of V120083 twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.
What is the current status of trial NCT03028870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 291 participants. The study started on 2017-03-14. Estimated completion is 2017-11-21.
What interventions are being tested in trial NCT03028870?
The interventions under investigation include: Placebo (DRUG), Naproxen (DRUG), V120083 (DRUG).
Who is sponsoring clinical trial NCT03028870?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.